Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARDUST trial of liraglutide for lower limb perfusion in type 2 diabetes with peripheral artery disease
2020-002940-22Phase 4Completed
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- May 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of liraglutide in arteriosclerosis obliterans and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Campania Luigi Vanvitelli. Primary endpoint: Change in lower-limb TcPO2. Started May 2021; status: completed.
02
Drugs
03
Conditions
arteriosclerosis obliteranstype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-002940-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002940-22.